Company Description
Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons.
It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.
It also processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications.
In addition, it offers Certex spinal fixation, Spider cervical plating, Streamline OCT, CervAlign, Axle interspinous fusion, Xpress minimally invasive pedicle screw, Fortex pedicle screw, Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation systems, and Silex sacroiliac joint fusion systems.
Further, it provides Calix for cervical and thoracolumbar applications, as well as Irix-C Cervical Integrated Fusion, Irix-A Lumbar Integrated Fusion, Fortilink, and Irix-A Lumbar integrated fusion systems; Coflex device for lumbar spinal stenosis; and CoFix implant for back and disc pain.
The company is headquartered in Belgrade, Montana.
| Country | United States |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 215 |
| CEO | Sean Browne |
Contact Details
Address: 664 Cruiser Lane Belgrade, Montana 59714 United States | |
| Phone | 406 388 0480 |
| Website | xtantmedical.com |
Stock Details
| Ticker Symbol | XTNT |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001453593 |
| CUSIP Number | 98420P308 |
| ISIN Number | US98420P3082 |
| Employer ID | 20-5313323 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Sean E. Browne | President, Chief Executive Officer and Director |
| Mark A. Schallenberger | Chief Operations Officer |
| Scott C. Neils | Chief Financial Officer |
| Catherine Lundy | Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SCHEDULE 13G | Filing |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Sep 11, 2024 | EFFECT | Notice of Effectiveness |
| Sep 11, 2024 | 424B3 | Prospectus |
| Sep 10, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Sep 9, 2024 | EFFECT | Notice of Effectiveness |
| Sep 9, 2024 | UPLOAD | Filing |
| Sep 4, 2024 | POS AM | Post-Effective amendments for registration statement |
| Sep 3, 2024 | S-3 | Registration statement under Securities Act of 1933 |